Trevi Therapeutics Inc (TRVI) 13F Holders & Ownership Data (223 Funds, Q2 2026)

TRVI ranks #2746 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

TRVI is a top-conviction position for NEA Management Company, LLC — at 15.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Fidelity has added to its TRVI position for two straight quarters, increasing it by $152.9M to reach $234.3M today.

Octagon Capital Advisors LP has trimmed its TRVI position for two straight quarters, cutting it by $29.4M while still holding $5.9M.

TRVI is down 0.7% today, but institutions show net buying of $333.3M this quarter — a divergence between today's price move and the underlying institutional flow.

TRVI reported a net loss of $42.8M in its latest fiscal year.

• Not yet profitable — net loss of $42.8M in the latest fiscal year
• Net income improved year over year, from -$47.9M to -$42.8M
• Operating cash flow was negative, using $42.1M in cash
• Current ratio of 19.66x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.06x equity — within a conventional range